Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

FDA DEPUTY CDMMISSIONER JOHN NORRIS WILL PROVIDE POLICY CONTINUITY at the top management level of the agency if and when FDA Com. Young moves up to a post at HHS. Norris, who according to a May 15 FDA press release will assume the deputy commissioner job on June 3, is a long time associate of Young's dating back to the Commissioner's former position as dean of the University of Rochester Medical School. He has served as a consultant to FDA since Young became commissioner last summer. The appointment of Norris ties up one of the remaining loose ends which has held up Young's anticipated move to HHS as Asst. Secty. for Health. The Deputy Commissioner slot has been vacant since January, when Mark Novitch, MD, a longtime FDA official, accepted a position with Upjohn. Heckler wants to settle on a new FDA Commissioner before moving Young to the department level job. The leading candidate to replace Young is said to be VA Medicine & Surgery Dept. medical director David Worthen, MD. Norris breaks two traditions associated with the FDA Deputy Commissioner job. As a lawyer, his background differs from the medical/scientific background of previous deputy commissioners. Secondly, while he has served as a consultant to the agency since Young became commissioner last summer, he does not have the long insider experience which former deputy commissioners like Novitch and Sherwin Gardner brought to the job. As a consultant to the agency, Norris has been involved in the development of Young's "action plan" for FDA. The document, intended to serve as a guideline for future FDA policy, is expected to be released soon. As deputy commissioner, Norris will be in a good position to help a new commissioner in the implementation of the action plan developed under Young. Since early this year, an FDA press release notes, Norris has also been "a member of Secretary Heckler's commission on the evaluation of pain. . .established by Congress to study the effects of pain in determining eligibility for social security or supplemental security income disability benefits." Commenting on Norris' appointment as Deputy, Young said his role, "like that of Dr. Novitch, will be that of Chief Operating Officer of FDA, the federal government's oldest consumer agency and one which has a regulatory impact on products, foods, drugs, cosmetics, medical and radiological devices, and veterinary medicines, representing .25 out of every dollar that consumers spend." Norris received his BA in econornics and political science from the University of Rochester. He has a masters in business administration from Cornell. Norris also has a law degree from Cornell Law School, where he was editor and chief of the Internatl. Law Review, The release notes that "founder and faculty editor and chief emeritus of the Ameican journal of Law and Medicine, Norris was the 1981 recipient of the honorary life membership award of the American Society of Law and Medicine."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts